Company · Public · UBX
Unity Biotechnology
Clinical-stage company developing medicines that selectively clear senescent cells, historically focused on ophthalmology and localized delivery.
Listing
Public
Ticker
UBX
Headquarters
South San Francisco, US
Founded
2011
Technology
Senolytics
Category
Longevity thesis
Local senolytic delivery avoids the systemic tolerability problems that have limited earlier senolytic candidates.
Programmes
- UBX1325Phase 2b
Diabetic macular edema
- UBX2050Preclinical
Ocular fibrosis
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.